Impax Laboratories (NASDAQ:IPXL) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.
Several other research firms have also issued reports on IPXL. Zacks Investment Research lowered shares of Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, October 20th. UBS Group upped their price target on shares of Impax Laboratories from $12.00 to $16.00 and gave the company a “sell” rating in a research report on Monday, October 30th. Cowen restated a “hold” rating and set a $16.00 price target on shares of Impax Laboratories in a research report on Friday, November 10th. Cantor Fitzgerald upped their price target on shares of Impax Laboratories from $25.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, November 10th. Finally, Canaccord Genuity set a $19.00 price objective on shares of Impax Laboratories and gave the company a “hold” rating in a research note on Monday, December 18th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $19.62.
Shares of Impax Laboratories (IPXL) opened at $19.60 on Friday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81. Impax Laboratories has a 1 year low of $7.75 and a 1 year high of $25.70. The stock has a market cap of $1,451.42, a PE ratio of -3.14, a price-to-earnings-growth ratio of 0.97 and a beta of 1.11.
TRADEMARK VIOLATION WARNING: “BidaskClub Lowers Impax Laboratories (IPXL) to Sell” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2018/02/18/bidaskclub-lowers-impax-laboratories-ipxl-to-sell.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.